Login to Your Account



Move Over PEG

Mersana Inks $334M Teva Deal for Long-Acting Cancer Drug

By Trista Morrison


Tuesday, April 13, 2010
Mersana Therapeutics Inc. is expected to announce on Tuesday a $334 million deal with Teva Pharmaceuticals Industries Ltd. for XMT-1107, a preclinical revival of the old antiangiogenic drug fumagillin. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription